Multiple Myeloma

>

Latest News

“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.
Mortality, Adverse Outcome Odds Higher in Multiple Myeloma PEM Population

April 28th 2025

Findings indicate a need to address protein-energy malnutrition in the treatment of those who have multiple myeloma with acute congestive heart failure.

Treatment with daratumumab-based combination therapies may drive minimal residual disease conversion rates in patients with newly diagnosed multiple myeloma.
Assessing CD38 Monoclonal Antibody-Based Regimens in NDMM

April 27th 2025

Final analysis data from the phase 3 ALCYONE trial support using frontline daratumumab-containing regimens for those with transplant-ineligible NDMM.
Daratumumab Combo Yields Sustained Benefits in Transplant-Ineligible NDMM

April 25th 2025

Disease control following radiotherapy appeared to be optimal in a retrospective cohort of patients with multiple myeloma.
Extent of Prior Therapy Does Not Impact Radiotherapy Response in Myeloma

April 21st 2025

UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications
UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications

April 18th 2025

Video Series
Video Interviews
Podcasts
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.
Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.

More News